Details About Generic Salt ::  Bisoprol

Main Medicine Class:: Beta-adrenergic blocker   

(bih-SO-pro-lahl FYU-mah-rate)

Zebeta

Class: Beta-adrenergic blocker

Drugs Class ::

 Action Blocks beta receptors, primarily affecting cardiovascular system (decreases heart rate, cardiac contractility and BP) and lungs (promotes bronchospasm).

Indications for Drugs ::

 Indications Hypertension. Unlabeled use(s): Angina pectoris; supraventricular tachycardias; premature ventricular contractions.

Drug Dose ::

 Route/Dosage

Hypertension

ADULTS: PO 5 to 20 mg qd. Dosage should be individualized; some patients may be given starting dose of 2.5 mg/day.

Contraindication ::

 Contraindications Hypersensitivity to beta-blockers; sinus bradycardia; greater than first-degree heart block; CHF unless secondary to tachyarrhythmia treatable with beta-blockers; overt cardiac failure; cardiogenic shock.

Drug Precautions ::

 Precautions

Pregnancy: Category C. Lactation: Undetermined. Children: Safety and efficacy not established. Anaphylaxis: Deaths have occurred; aggressive therapy may be required. CHF: Administer cautiously in patients whose CHF is controlled by digitalis and diuretics. Diabetes mellitus: May mask symptoms of hypoglycemia (eg, tachycardia, BP changes). May potentiate insulin-induced hypoglycemia. Nonallergic bronchospastic disease (eg, chronic bronchitis, emphysema): In general, beta-blockers are not given to patients with bronchospastic diseases. Peripheral vascular disease: May precipitate or aggravate symptoms of arterial insufficiency. Renal/hepatic impairment: Reduce daily dose. Thyrotoxicosis: May mask clinical signs (eg, tachycardia) of developing or continuing hyperthyroidism. Abrupt withdrawal may exacerbate symptoms of hyperthyroidism, including thyroid storm.

Drug Side Effects ::

 Adverse Reactions

CV: Hypotension; bradycardia; CHF; cold extremities; second- or third-degree heart block. CNS: Insomnia; fatigue; dizziness; depression; lethargy; drowsiness; forgetfulness; anxiety; headache; slurred speech. DERM: Rash; hives; alopecia. EENT: Dry eyes; blurred vision; tinnitus; sore throat. GI: Nausea; vomiting; diarrhea; constipation; abdominal pain; dry mouth. GU: Impotence; painful, difficult or frequent urination; increased creatinine and BUN. HEMA: Agranulocytosis; thrombocytopenic purpura. HEPA: Elevated liver function test results. META: Hyperglycemia; hypoglycemia. RESP: Bronchospasm; dyspnea; wheezing. OTHER: Weight changes; fever; facial swelling; muscle weakness; increased serum uric acid, potassium and phosphorus; elevated serum lipids; possible development of antinuclear antibodies.

Drug Mode of Action ::  

 Action Blocks beta receptors, primarily affecting cardiovascular system (decreases heart rate, cardiac contractility and BP) and lungs (promotes bronchospasm).

Drug Interactions ::

 Interactions

Clonidine: May enhance or reverse antihypertensive effect; potentially life-threatening situations may occur, especially on withdrawal. NSAIDs: Some agents may impair antihypertensive effect. Prazosin: May increase orthostatic hypotension. Verapamil: May potentiate effects of both drugs.

Drug Assesment ::

 Assessment/Interventions

• Obtain patient history, including drug history and any known allergies. Note CHF, diabetes mellitus or hypertension.
• Assess for withdrawal syndrome. Beta-blocker withdrawal syndrome (eg, hypertension, tachycardia, anxiety, angina, MI) may occur 1 to 2 wk after sudden discontinuation. Gradually withdraw therapy over 1 to 2 wk if possible.
• Ensure that baseline AST, ALT, uric acid, creatinine, BUN, serum potassium, glucose and phosphorus levels have been obtained before starting treatment with this medication.
• Monitor BP and pulse prior to each dosage.
• In diabetic patients, monitor blood glucose level and diabetic medications closely.
• Carefully monitor patients with CHF, COPD or asthma and report changes in cardiac or respiratory status to physician.

Drug Storage/Management ::

 Administration/Storage

• May be given without regard to meals.

Drug Notes ::

 Patient/Family Education

• Explain that drug will be tapered slowly before stopping to prevent rebound symptoms and adverse effects.
• Teach patients how to monitor pulse before taking oral medication and advise to contact physician if pulse is < 50 bpm.
• Inform diabetic patient to monitor blood glucose level closely.
• Instruct patient to report the following symptoms to physician: Dizziness, decreased pulse, shortness of breath, confusion, rash or any unusual bleeding.
• Advise patient that drug may cause drowsiness, and to use caution while driving or performing other tasks requiring mental alertness.
• Instruct patient not to take otc medications (including diet aids, cold or nasal preparations [alpha-adrenergic stimulants]) without consulting physician.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.